

## Editorial

# Introduction to the *Journal of Clinical & Translational Ophthalmology*

Jack V. Greiner <sup>1,2,3,4</sup> 

- <sup>1</sup> Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA; jack\_greiner@meei.harvard.edu
- <sup>2</sup> Schepens Eye Research Institute of Massachusetts Eye and Ear Infirmary, 20 Staniford Street, Boston, MA 02114, USA
- <sup>3</sup> Clinical Eye Research of Boston and Boston Ocular Surface Center, 5 Whittier Place, Suite 102, Boston, MA 02114 and 955 Main Street, Suite 307, Winchester, MA 01890, USA
- <sup>4</sup> Department of Ophthalmology, Tufts University School of Medicine, Boston, MA 02111, USA

The primary objective of the *Journal of Clinical & Translational Ophthalmology* (JCTO) (ISSN: 2813-1053) [1] is to establish a forum that allows the basic science researcher to gain insight into current clinically relevant questions, while simultaneously providing clinicians with a better understanding of the underlying pathophysiology of the clinical presentations that they experience on a first-hand basis. It is our belief that this approach will lead to the most rapid and efficacious progress in the prevention, diagnosis, and treatment of ocular disease. This Journal is dedicated to facilitating this translational philosophy by providing curated, peer-reviewed articles that cover a wide range of fields in ophthalmology that are of interest to the general practitioner, the specialist, and those involved in basic eye research.

As outlined in the 2019 World Health Organization Report on Vision, at least 2.2 billion people globally have vision impairment; of these, at least one billion have an issue that could have been treated or prevented [2]. Compromised vision critically impacts daily life, and such preventable and/or treatable scenarios are even more consequential on an individual, community and global basis, given the increase in the world's population and life expectancy. Introducing a new ophthalmology journal that embraces both clinical and basic science research, particularly as it relates to translational medicine, is thus especially important, as it provides a novel educational platform that addresses the intersection of both of these aspects of ophthalmic research, with the expectation that this type of nexus will enhance the development of real-world solutions to eye disease.

We look forward to publishing high-interest, peer-reviewed manuscripts covering a wide range of ophthalmic conditions, including original research papers, review articles, short communications, case studies, and commentaries. It is the intention of the Journal to encourage a robust response from the readership as it relates to these contemporary topics in order to provide a more dynamic experience that will undoubtedly contribute to the translational mission of the Journal. Topics of interest include, but are not limited to:

- Cataracts and accommodative abnormalities
- Color deficiencies
- Corneal conditions
- Dry eye syndromes
- Eyelids and related abnormalities
- Glaucoma
- Infections of the eye and adnexa
- Lacrimal system abnormalities
- Ocular oncology
- Ocular inflammatory diseases
- Ophthalmic plastic and reconstructive surgery



**Citation:** Greiner, J.V. Introduction to the *Journal of Clinical & Translational Ophthalmology*. *J. Clin. Transl. Ophthalmol.* **2023**, *1*, 1–2. <https://doi.org/10.3390/jcto1010001>

Received: 8 September 2022

Accepted: 9 September 2022

Published: 28 September 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

- Presbyopia
- Refractive surgery
- Strabismus and ocular motility
- Surgical procedures
- Uveitis
- Vitreoretinal conditions
- Vision loss

The *Journal of Clinical & Translational Ophthalmology* is dedicated to offering a unique educational experience for both the clinician and basic science researcher that will provide a foundation for novel translational applications for the prevention and treatment of ocular disorders. To facilitate our mission, we have assembled an internationally distinguished editorial board that is supported by an editorial office staff and publisher that recognize the timely importance of this type of journal.

On behalf of the Journal's founders, editorial board, and staff, we look forward to your contributions to the *Journal of Clinical & Translational Ophthalmology* and, more importantly, to their impact on the advancement of ophthalmic care.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The author declares no conflict of interest.

## References

1. *Journal of Clinical & Translational Ophthalmology* Home Page. Available online: <https://www.mdpi.com/journal/jcto> (accessed on 7 September 2022).
2. *World Report on Vision*; World Health Organization: Geneva, Switzerland, 2019; License: CC BY-NC-SA 3.0 IGO.

## Short Biography of Author



**Prof. Dr. Jack V. Greiner** is an ophthalmologist, physician and surgeon, optometrist, teacher, biomedical research scientist and Editor-in-Chief of the *Journal of Clinical & Translational Ophthalmology*. Prof. Dr. **Greiner** is currently an Associate Professor of Ophthalmology at Harvard Medical School, Boston, MA, USA; the Director of both the Boston Ocular Surface Center and Clinical Eye Research of Boston, MA, USA; an Adjunct Clinical Associate Professor of Ophthalmology at Tufts University School of Medicine, Boston, MA, USA; and an Affiliate Clinical Professor of Surgery (Ophthalmology) at University of New England College of Osteopathic Medicine, Biddeford, ME, USA. He has authored over 200 publications in the scientific and medical literature, has delivered over 200 lectures at national and international meetings, and holds six U.S. patents and corresponding foreign patents in the treatment areas of dry eye diseases and the integument. Additionally, he has participated in over 200 FDA clinical trials as a principal investigator or sub-investigator to assess the safety and efficacy of novel ophthalmic therapeutic interventions.